# OnCo record paper-karmma-3-ide-cel-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-karmma-3-ide-cel-nejm-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-karmma-3-ide-cel-nejm-2023" ;
  schema:name "KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma"@en ;
  schema:description "The first randomised CAR-T trial in myeloma tripled median progression-free survival (13.3 versus 4.4 months) compared with standard combinations after two to four prior lines."@en ;
  schema:url <https://onco.cc/key-papers/paper-karmma-3-ide-cel-nejm-2023/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2213614>, <https://clinicaltrials.gov/study/NCT03651128> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2213614> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al." ;
  onco:related <https://onco.cc/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/> ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/bcma/> ;
  onco:drugs <https://onco.cc/drugs/idecabtagene-vicleucel/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/orr/>, <https://onco.cc/terms/crs/> ;
  onco:trials <https://onco.cc/trials/karmma-3/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:journals <https://onco.cc/journals/nejm/> .